We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Noninvasive Technology Accurately Detects Malaria Through the Skin

By LabMedica International staff writers
Posted on 07 Jan 2014
Vapor nanobubbles rapidly detect malaria through the skin. More...
The noninvasive technology accurately detects low levels of malaria infection in seconds with a laser scanner.

The new diagnostic technology uses a low-powered laser that creates tiny vapor nanobubbles inside malaria-infected cells. The bursting bubbles have a unique acoustic signature that allows for a very sensitive diagnosis.

The vapor nanobubble technology requires no dyes or diagnostic chemicals, and there is no need to draw blood. The new technology uses a low-powered laser that creates tiny vapor nanobubbles inside malaria-infected cells. The bursting bubbles have a unique acoustic signature that allows for an extremely sensitive diagnosis.

“Ours is the first through-the-skin method that’s been shown to rapidly and accurately detect malaria in seconds without the use of blood sampling or reagents,” said lead investigator Dmitri Lapotko, a Rice University (Houston, TX, USA) scientist who invented the vapor nanobubble technology. The diagnosis and screening will be supported by a low-cost, battery-powered portable device that can be operated by nonmedical personnel. One device should be able to screen up to 200,000 people per year, with the cost of diagnosis estimated to be below 50 cents, he said.

The preclinical study published in the January 2014 Proceedings of the National Academy of Sciences of the United States of America (PNAS) shows that Rice’s technology detected even a single malaria-infected cell among a million normal cells with zero false-positive readings.

Inexpensive rapid diagnostic tests exist, but they lack sensitivity and reliability. The gold standard for diagnosing malaria is a “blood smear” test, which requires a sample of the patient’s blood, a trained laboratory technician, chemical reagents, and high-quality microscope. These are often unavailable in low-resource hospitals and clinics in the developing world.

“The vapor nanobubble technology for malaria detection is distinct from all previous diagnostic approaches,” said study coauthor Dr. David Sullivan, a malaria clinician and researcher at Malaria Research Institute at Johns Hopkins University. “The vapor nanobubble transdermal detection method adds a new dimension to malaria diagnostics, and it has the potential to support rapid, high-throughput and highly sensitive diagnosis and screening by nonmedical personnel under field conditions.”

The transdermal diagnostic method takes advantage of the optical properties and nanosize of hemozoin, a nanoparticle produced by a malaria parasite inside red blood cell. Hemozoin crystals are not found in normal red blood cells.

Lapotko, a faculty fellow in biochemistry and cell biology and in physics and astronomy at Rice University, and lead coauthor Ekaterina Lukianova-Hleb found that hemozoin absorbs the energy from a short laser pulse and creates a transient vapor nanobubble. This short-lived vapor nanobubble emerges around the hemozoin nanoparticle and it is detected both acoustically and optically. In the study, the researchers found that acoustic detection of nanobubbles made it possible to detect malaria with extraordinary sensitivity.

The first trials of the technology in humans are expected to begin in Houston in early 2014.

Related Links:

Rice University



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Neuron-derived extracellular vesicles carry many biomarker candidates for Alzheimer’s (S Chinnathambi et al., Brain Network Disorders (2025). doi.org/10.1016/j.bnd.2024.12.006)

Neuron-Derived Extracellular Vesicles Could Improve Alzheimer’s Diagnosis

Alzheimer’s disease is becoming increasingly common as global populations age, yet effective treatments for advanced stages remain limited. Early detection is therefore critical, but current diagnostic... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.